SHJBF (Shanghai Junshi Biosciences Co) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHJBF Shanghai Junshi Biosciences Co Ltd SHJBF
72 GF Score
Price $3.35
GF Value $5.31
! 4 Warning Signs
View Full Analysis

What is Shanghai Junshi Biosciences Co SpecialCharges?

Special Charges only applies to banks.

SHJBF
72GF Score
Shanghai Junshi Biosciences Co Ltd SHJBF
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Shanghai Junshi Biosciences Co (SHJBF) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Junshi Biosciences Co stock appears to be undervalued. The current stock price of $3.35 is trading 36.9% below its estimated GF Value™ of $5.31.

Key valuation signals for SHJBF:

  • SpecialCharges:
  • GF Value™: $5.31 vs. price of $3.35 (36.9% below fair value)
  • GF Score™: 72/100 with 4 warning signs

No single metric tells the full story. See the SHJBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Junshi Biosciences Co Business Description

Other Exchanges 01877:Hong Kong688180:China
Address No. 987 Cai Lun Road, Level 4, China (Shanghai) Pilot Free Trade Zone, Shanghai, CHN
Shanghai Junshi Biosciences Co Ltd is mainly involved in the discovery, development, and commercialisation of therapeutic drugs. It focuses on the development and commercialization of several kinds of drugs, ranging from monoclonal antibodies to various drug modalities, including small molecules, ADCs, bi-specific or multi-specific antibodies, fusion proteins, nucleic acid drugs, and vaccines, as well as the exploration of next-generation therapies, including those for cancer and autoimmune diseases. The Group's portfolio includes commercialized drugs such as Tuoyi, Junmaikang, Mindewei, and Junshida, as well as products in clinical studies or in the marketing application stage. Geographically, it derives maximum revenue from Mainland China, and the rest from USA, India, and other markets.
72GF Score

Get the complete analysis for SHJBF

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.35
Price
$5.31
GF Value